Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Radiation-guided drug delivery to mouse models of lung cancer.

Hariri G, Yan H, Wang H, Han Z, Hallahan DE.

Clin Cancer Res. 2010 Oct 15;16(20):4968-77. doi: 10.1158/1078-0432.CCR-10-0969. Epub 2010 Aug 27.

2.

Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked "nanosponge" network for lung cancer chemotherapy.

Hariri G, Edwards AD, Merrill TB, Greenbaum JM, van der Ende AE, Harth E.

Mol Pharm. 2014 Jan 6;11(1):265-75. doi: 10.1021/mp400432b. Epub 2013 Nov 22.

PMID:
24215299
3.

Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.

Zhou Q, Ching AK, Leung WK, Szeto CY, Ho SM, Chan PK, Yuan YF, Lai PB, Yeo W, Wong N.

Int J Oncol. 2011 Mar;38(3):721-31. doi: 10.3892/ijo.2011.902. Epub 2011 Jan 14.

PMID:
21240457
4.

Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.

Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z.

Recent Pat Anticancer Drug Discov. 2009 Nov;4(3):262-72. Review.

PMID:
19538176
5.

S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.

Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

J Surg Oncol. 2016 Mar;113(4):413-9. doi: 10.1002/jso.24147. Epub 2016 Jan 12.

PMID:
27100026
6.

Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.

Zhang L, Marrano P, Kumar S, Leadley M, Elias E, Thorner P, Baruchel S.

Clin Cancer Res. 2013 Nov 1;19(21):5972-83. doi: 10.1158/1078-0432.CCR-13-1485. Epub 2013 Aug 29.

7.

Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.

Lowery A, Onishko H, Hallahan DE, Han Z.

J Control Release. 2011 Feb 28;150(1):117-24. doi: 10.1016/j.jconrel.2010.11.006. Epub 2010 Nov 12.

8.

SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.

Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D.

Mol Cancer Ther. 2016 Apr;15(4):680-8. doi: 10.1158/1535-7163.MCT-15-0764. Epub 2016 Feb 1.

9.

Radiation-Guided Peptide Delivery in a Mouse Model of Nasopharyngeal Carcinoma.

Lin PC, He JY, Le YY, Du KX, Zhu WF, Peng QQ, Dong YP, Li JL, Wu JX.

Biomed Res Int. 2016;2016:5382047. Epub 2016 Sep 21.

10.

Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.

Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, Furukawa H, Hayashi H, Nakamura K, Inokuchi M, Nakagawara H, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fujimura T, Masakazu Y, Hirakawa K, Ohta T.

Oncol Rep. 2014 Jul;32(1):89-96. doi: 10.3892/or.2014.3210. Epub 2014 May 23.

PMID:
24859429
11.

nab-Paclitaxel mechanisms of action and delivery.

Yardley DA.

J Control Release. 2013 Sep 28;170(3):365-72. doi: 10.1016/j.jconrel.2013.05.041. Epub 2013 Jun 11. Review.

PMID:
23770008
12.

Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.

Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH.

Pancreas. 2016 Mar;45(3):425-33. doi: 10.1097/MPA.0000000000000501.

PMID:
26495780
13.

Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.

Liu J, Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, Kong D.

Int J Nanomedicine. 2010 Dec 22;6:59-69. doi: 10.2147/IJN.S14601.

14.

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration.

Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, Li Y, Zhou S, Hou S, Carleton M, Klinghoffer RA, Palmisano M, Chopra R.

Cancer Chemother Pharmacol. 2015 Oct;76(4):699-712. doi: 10.1007/s00280-015-2833-5. Epub 2015 Aug 1.

15.

Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.

Zhang C, Qu G, Sun Y, Wu X, Yao Z, Guo Q, Ding Q, Yuan S, Shen Z, Ping Q, Zhou H.

Biomaterials. 2008 Mar;29(9):1233-41.

PMID:
18093646
16.

Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.

Passarella RJ, Spratt DE, van der Ende AE, Phillips JG, Wu H, Sathiyakumar V, Zhou L, Hallahan DE, Harth E, Diaz R.

Cancer Res. 2010 Jun 1;70(11):4550-9. doi: 10.1158/0008-5472.CAN-10-0339. Epub 2010 May 18.

17.

Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells.

Kim JC, Kim JS, Saha D, Cao Q, Shyr Y, Choy H.

Radiother Oncol. 2003 Sep;68(3):305-13.

PMID:
13129641
18.

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.

Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ.

Anticancer Drugs. 2008 Oct;19(9):899-909. doi: 10.1097/CAD.0b013e32830f9046.

PMID:
18766004
19.

130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.

Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz TA, Milas L, Mason KA.

Clin Cancer Res. 2007 Mar 15;13(6):1868-74.

20.

TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation.

Wang H, Yan H, Fu A, Han M, Hallahan D, Han Z.

PLoS One. 2010 Aug 11;5(8):e12051. doi: 10.1371/journal.pone.0012051.

Supplemental Content

Support Center